Welcome to our dedicated page for Design Therapeutics SEC filings (Ticker: DSGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Design Therapeutics, Inc. filings document the regulatory disclosures of a Nasdaq-listed, clinical-stage biotechnology company developing GeneTAC® small-molecule therapies for serious degenerative genetic diseases. Its 8-K reports furnish financial results, corporate presentations, pipeline updates, and material governance events tied to board appointments, resignations, committee assignments, director compensation, and indemnification arrangements.
Proxy materials describe annual meeting matters, director elections, auditor ratification, stockholder voting procedures, and board structure. The filing record also identifies the company’s common stock registration on The Nasdaq Global Select Market, emerging growth company status, and public-company disclosure framework for operations, capital structure, governance, and risk reporting.
Design Therapeutics, Inc. reported a net loss of $17.6 million for the quarter ended March 31, 2026, as it continues investing in its GeneTAC small-molecule pipeline. Research and development expenses were $14.4 million and general and administrative expenses were $5.3 million.
The company ended the quarter with $222.8 million in cash, cash equivalents and investment securities, which it believes will fund operations for more than 12 months. Design also raised $19.9 million of net proceeds by selling 2,006,550 shares through its at-the-market program. Key programs include DT-216P2 for Friedreich ataxia, DT-168 for Fuchs endothelial corneal dystrophy and DT-818 for myotonic dystrophy type-1, with multiple clinical readouts anticipated from 2026 onward.
Design Therapeutics, Inc. reported first quarter 2026 results and highlighted progress across its GeneTAC® pipeline. The company posted a net loss of $17.6 million for the quarter, with research and development expenses of $14.4 million and general and administrative expenses of $5.3 million.
Cash, cash equivalents and investment securities totaled $222.8 million as of March 31, 2026, which Design expects to fund planned operations into 2029. The RESTORE-FA Phase 1/2 trial of DT-216P2 in Friedreich ataxia is ongoing, with frataxin biomarker data expected in the second half of 2026.
Additional programs include a Phase 2 biomarker trial of DT-168 in Fuchs endothelial corneal dystrophy with data anticipated in the second half of 2026, and a Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type-1 expected to begin dosing in the first half of 2026, with results anticipated in 2027. The company also appointed David Shapiro, M.D., to its board of directors to strengthen clinical and regulatory expertise.
Design Therapeutics, Inc. is holding its 2026 virtual annual meeting of stockholders on June 9, 2026 at 8:00 a.m. Pacific Time. Stockholders of record as of April 14, 2026, when 62,441,429 shares of common stock were outstanding, may attend and vote.
Stockholders will vote on electing one Class II director, Simeon George, M.D., to a three-year term ending at the 2029 annual meeting and on ratifying Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026. The Board recommends voting in favor of both proposals.
The proxy statement also outlines board structure and independence, committee responsibilities, anti-hedging and anti-pledging policies, major stockholders’ ownership, and detailed 2025 compensation for key executives, including salary, cash bonuses and stock option awards.
Design Therapeutics director David Shapiro received new stock option awards, increasing his potential equity stake without any open-market trading. On March 31, 2026, he was granted options for 60,000 shares of common stock at an exercise price of $10.64 per share, expiring March 30, 2036. These options vest in equal monthly installments over 36 months following March 31, 2026. He also received a separate option for 7,500 shares at the same $10.64 exercise price, expiring March 30, 2036, vesting in equal monthly installments over 12 months following March 31, 2026. Both grants are reported as direct ownership and represent compensation awards rather than share purchases or sales.
Design Therapeutics, Inc. filed a Form 3 insider report identifying David Shapiro as a director of the company. The provided data shows no reportable transactions or holdings, indicating this filing serves only to register his status as a reporting person.
Design Therapeutics, Inc. reported that its Board appointed David Shapiro, M.D., as a Class III director effective March 31, 2026, with a term running until the 2027 annual meeting of stockholders. He will also serve on the Nominating and Corporate Governance Committee.
Under the company’s non-employee director compensation policy, Dr. Shapiro will receive an annual cash retainer of $40,000 for Board service and $5,000 for Nominating Committee service. He was granted an initial option to purchase 60,000 shares of common stock vesting monthly over three years and a prorated annual option for 7,500 shares vesting monthly over one year.
SR One Capital Fund I Aggregator, SR One Capital Partners I, SR One Capital Management and Simeon George filed an amended beneficial ownership report for Design Therapeutics, Inc. common stock. Aggregator, Partners I and Parent each report beneficial ownership of 6,526,476 shares, representing 10.6% of the outstanding common stock.
Dr. Simeon George reports beneficial ownership of 6,607,892 shares, or 10.7% of the class, including 81,416 shares over which he has sole voting and dispositive power and 6,526,476 shares over which he shares voting and dispositive power. The filing states that their percentage ownership decreased by more than 1% because the issuer’s outstanding common stock increased to 61,672,279 shares as of March 2, 2026, and notes that none of the reporting persons has traded the stock in the last 60 days.
Design Therapeutics, Inc. is a clinical-stage biopharma company developing GeneTAC small‑molecule genomic medicines to treat nucleotide repeat expansion diseases by modulating gene transcription at the DNA level. Its lead programs target Friedreich ataxia (FA), Fuchs endothelial corneal dystrophy (FECD), myotonic dystrophy type‑1 (DM1) and Huntington’s disease (HD).
Lead FA candidate DT‑216P2, a reformulation of DT‑216, is in the RESTORE‑FA Phase 1/2 multiple‑ascending dose trial after Phase 1 data showed FXN increases with the prior formulation and improved pharmacokinetics with DT‑216P2. An update on frataxin levels after 12 weeks of dosing is expected in the second half of 2026.
Eye‑drop candidate DT‑168 for FECD has completed a Phase 1 trial in healthy volunteers with favorable safety and is in a Phase 2 biomarker study, with data also expected in the second half of 2026. DM1 candidate DT‑818 has preclinical data showing over 90% toxic RNA foci reduction and has regulatory clearance for a Phase 1 MAD trial, with patient dosing planned in 2026. HD candidates have shown selective mutant huntingtin reduction in patient cells and a mouse model while preserving wild‑type huntingtin.
Design Therapeutics reported higher operating expenses and a wider loss in 2025 as it advanced multiple GeneTAC® programs. Research and development spending was $59.1 million for the year, up from $44.4 million, and net loss increased to $69.8 million from $49.6 million.
Fourth-quarter 2025 net loss was $16.0 million, or $0.27 per share. The company ended 2025 with $219.8 million in cash, cash equivalents and investment securities, which it expects will fund planned operations into 2029.
Clinically, Design continues dosing Friedreich ataxia patients with DT-216P2 and running a Phase 2 biomarker trial of DT-168 in Fuchs endothelial corneal dystrophy, with data from both anticipated in the second half of 2026. It plans to begin dosing myotonic dystrophy type-1 patients with DT-818 in a Phase 1 trial in the first half of 2026, with results expected in 2027, while also progressing preclinical work in Huntington’s disease.